Literature DB >> 17693639

Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity.

Sokol V Todi1, Mario N Laco, Brett J Winborn, Sue M Travis, Hsiang M Wen, Henry L Paulson.   

Abstract

Ataxin-3, a deubiquitinating enzyme, is the disease protein in spinocerebellar ataxia type 3, one of many neurodegenerative disorders caused by polyglutamine expansion. Little is known about the cellular regulation of ataxin-3. This is an important issue, since growing evidence links disease protein context to pathogenesis in polyglutamine disorders. Expanded ataxin-3, for example, is more neurotoxic in fruit fly models when its active site cysteine is mutated (1). We therefore sought to determine the influence of ataxin-3 enzymatic activity on various cellular properties. Here we present evidence that the catalytic activity of ataxin-3 regulates its cellular turnover, ubiquitination, and subcellular distribution. Cellular protein levels of catalytically inactive ataxin-3 were much higher than those of active ataxin-3, in part reflecting slower degradation. In vitro studies revealed that inactive ataxin-3 was more slowly degraded by the proteasome and that this degradation occurred independent of ubiquitination. Slower degradation of inactive ataxin-3 correlated with reduced interaction with the proteasome shuttle protein, VCP/p97. Enzymatically active ataxin-3 also showed a greater tendency to concentrate in the nucleus, where it colocalized with the proteasome in subnuclear foci. Taken together, these and other findings suggest that the catalytic activity of this disease-linked deubiquitinating enzyme regulates several of its cellular properties, which in turn may influence disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693639     DOI: 10.1074/jbc.M704126200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.

Authors:  Joanna R Sutton; Jessica R Blount; Kozeta Libohova; Wei-Ling Tsou; Gnanada S Joshi; Henry L Paulson; Maria do Carmo Costa; K Matthew Scaglione; Sokol V Todi
Journal:  Hum Mol Genet       Date:  2017-04-15       Impact factor: 6.150

3.  The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster.

Authors:  Wei-Ling Tsou; Michelle Ouyang; Ryan R Hosking; Joanna R Sutton; Jessica R Blount; Aaron A Burr; Sokol V Todi
Journal:  Neurobiol Dis       Date:  2015-05-22       Impact factor: 5.996

4.  Quantifying prefibrillar amyloids in vitro by using a "thioflavin-like" spectroscopic method.

Authors:  Ashley A Reinke; Gelareh A Abulwerdi; Jason E Gestwicki
Journal:  Chembiochem       Date:  2010-09-03       Impact factor: 3.164

5.  Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23.

Authors:  Jessica R Blount; Wei-Ling Tsou; Gorica Ristic; Aaron A Burr; Michelle Ouyang; Holland Galante; K Matthew Scaglione; Sokol V Todi
Journal:  Nat Commun       Date:  2014-08-21       Impact factor: 14.919

6.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

7.  Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3.

Authors:  Giuseppe Nicastro; Sokol V Todi; Ezgi Karaca; Alexandre M J J Bonvin; Henry L Paulson; Annalisa Pastore
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

8.  Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties.

Authors:  Ginny Marie Harris; Katerina Dodelzon; Lijie Gong; Pedro Gonzalez-Alegre; Henry L Paulson
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

9.  Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3).

Authors:  Conceição Bettencourt; Cristina Santos; Rafael Montiel; Maria do Carmo Costa; Pablo Cruz-Morales; Liliana Ribeiro Santos; Nelson Simões; Teresa Kay; João Vasconcelos; Patrícia Maciel; Manuela Lima
Journal:  Neurogenetics       Date:  2009-08-28       Impact factor: 2.660

10.  In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.

Authors:  Aislinn J Williams; Tina M Knutson; Veronica F Colomer Gould; Henry L Paulson
Journal:  Neurobiol Dis       Date:  2008-11-08       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.